SOCE channel inhibitors have successfully been used to reduce production of pro‐inflammatory cytokines (IFNγ, interleukin IL‐2, IL‐17) by certain T cell subsets from the LP of IBD patients (Di Sabatino et al, 2009). Here, IFNG is linked to inflammatory bowel disease.